A detailed history of Lido Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Lido Advisors, LLC holds 24,064 shares of VRTX stock, worth $12.1 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
24,064
Previous 1,500 1504.27%
Holding current value
$12.1 Million
Previous $627,000 1698.88%
% of portfolio
0.06%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$392.81 - $485.53 $208,189 - $257,330
530 Added 2.25%
24,064 $11.3 Million
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $36,284 - $39,701
-89 Reduced 0.38%
23,534 $9.84 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $5.26 Million - $6.3 Million
-15,330 Reduced 39.36%
23,623 $9.61 Million
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $7.36 Million - $7.89 Million
21,761 Added 126.58%
38,953 $13.5 Million
Q2 2023

Aug 09, 2023

SELL
$314.42 - $351.91 $2.23 Million - $2.49 Million
-7,087 Reduced 29.19%
17,192 $6.05 Million
Q1 2023

May 15, 2023

SELL
$283.23 - $323.1 $1.12 Million - $1.28 Million
-3,953 Reduced 14.0%
24,279 $7.65 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $3.5 Million - $3.93 Million
12,234 Added 76.47%
28,232 $8.15 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $3.25 Million - $3.62 Million
11,851 Added 285.77%
15,998 $4.63 Million
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $21,616 - $26,914
92 Added 2.27%
4,147 $1.17 Million
Q1 2022

May 17, 2022

BUY
$221.42 - $260.97 $157,651 - $185,810
712 Added 21.3%
4,055 $1.06 Million
Q4 2021

Feb 15, 2022

BUY
$177.01 - $223.45 $179,311 - $226,354
1,013 Added 43.48%
3,343 $734,000
Q3 2021

Feb 15, 2022

SELL
$181.39 - $202.99 $478,506 - $535,487
-2,638 Reduced 53.1%
2,330 $422,000
Q3 2021

Nov 12, 2021

BUY
$181.39 - $202.99 $532,016 - $595,369
2,933 Added 144.13%
4,968 $423,000
Q2 2021

Aug 12, 2021

BUY
$187.49 - $221.1 $40,497 - $47,757
216 Added 11.87%
2,035 $410,000
Q1 2021

May 13, 2021

SELL
$207.02 - $241.31 $26,912 - $31,370
-130 Reduced 6.67%
1,819 $391,000
Q4 2020

Feb 08, 2021

BUY
$207.01 - $276.09 $26,911 - $35,891
130 Added 7.15%
1,949 $460,000
Q3 2020

Nov 12, 2020

BUY
$255.65 - $303.1 $53,942 - $63,954
211 Added 13.12%
1,819 $495,000
Q2 2020

Aug 12, 2020

BUY
$225.48 - $295.8 $28,861 - $37,862
128 Added 8.65%
1,608 $467,000
Q1 2020

May 13, 2020

BUY
$199.77 - $247.81 $8,989 - $11,151
45 Added 3.14%
1,480 $352,000
Q4 2019

Feb 07, 2020

BUY
$166.71 - $223.91 $4,167 - $5,597
25 Added 1.77%
1,435 $314,000
Q3 2019

Nov 12, 2019

BUY
$166.23 - $187.09 $2,493 - $2,806
15 Added 1.08%
1,410 $239,000
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $4,279 - $4,949
26 Added 1.9%
1,395 $255,000
Q1 2019

May 10, 2019

SELL
$163.73 - $194.7 $3,602 - $4,283
-22 Reduced 1.58%
1,369 $251,000
Q4 2018

Feb 14, 2019

BUY
$151.91 - $192.21 $2,734 - $3,459
18 Added 1.31%
1,391 $230,000
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $8,218 - $9,444
49 Added 3.7%
1,373 $264,000
Q2 2018

Aug 14, 2018

SELL
$145.72 - $169.96 $194,244 - $226,556
-1,333 Reduced 50.17%
1,324 $225,000
Q1 2018

May 10, 2018

BUY
$151.6 - $177.13 $402,801 - $470,634
2,657 New
2,657 $433,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Lido Advisors, LLC Portfolio

Follow Lido Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lido Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lido Advisors, LLC with notifications on news.